About The Study:
Atopic dermatitis (AD), often referred to as eczema, is a chronic skin condition characterized by red, itchy, inflamed skin. It can affect people of all ages and the condition’s severity can vary, with symptoms ranging from mild discomfort to severe itching and inflammation that disrupt daily life. Some treatments for AD include topical steroids, moisturizers, antihistamines, topical calcineurin inhibitors, etc. Some people have a hard time finding a treatment to work based on the severity of their condition.
At Rochester Clinical Research we are currently enrolling adolescents who are between the ages of 12-18 years old who have diagnosed atopic dermatitis or eczema for a research study. The study is looking at the effectiveness of a monoclonal antibody in adolescents with moderate-severe atopic dermatitis. The experimental product will be delivered via seven injections over the span of 18 weeks. A similar study has been completed in adults with good efficacy and was well tolerated. There is a 30% chance of placebo in this study.
Compensation will be provided and study-related care is available to participants at no cost and health insurance is not required nor needed.
Qualifications
- Must be 12-18 years old
- Diagnosis of moderate to severe atopic dermatitis for at least 6 months
- Have had an inadequate response to topical corticosteroids in the past
- *Please note, many other qualifications apply